Adaptimmune Therapeutics plc (ADAP) News

Adaptimmune Therapeutics plc (ADAP): $1.86

0.06 (+3.33%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ADAP to Watchlist
Sign Up

Industry: Biotech


Ranked

of 399

in industry

Filter ADAP News Items

ADAP News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ADAP News Highlights

  • For ADAP, its 30 day story count is now at 4.
  • Over the past 13 days, the trend for ADAP's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about ADAP are GOLD and MESA.

Latest ADAP News From Around the Web

Below are the latest news stories about ADAPTIMMUNE THERAPEUTICS PLC that investors may wish to consider to help them evaluate ADAP as an investment opportunity.

Publication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcoma

-The response rate was 44% in patients with late-stage, metastatic synovial sarcoma after a single dose of afami-cel -- Based on these results, the Company initiated a Phase 2 trial with afami-cel for people with sarcoma, SPEARHEAD-1, and these data are being used to support a rolling BLA submission for approval -Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 9, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to ...

Yahoo | January 9, 2023

Even after rising 48% this past week, Adaptimmune Therapeutics (NASDAQ:ADAP) shareholders are still down 72% over the past five years

Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders will doubtless be very grateful to see the share price up 98...

Yahoo | January 8, 2023

Mesa Labs and Eldorado Gold have been highlighted as Zacks Bull and Bear of the Day

Mesa Labs and Eldorado Gold are part of the Zacks Bull and Bear of the Day article.

Yahoo | December 28, 2022

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.

Yahoo | December 27, 2022

Adaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial Sarcoma

- Afami-cel has the potential to be the first approved engineered TCR T-cell therapy for a solid tumor - -Synovial sarcoma has a high unmet medical need and the pivotal trial met its primary endpoint with an overall response rate of ~39% after a single dose of afami-cel -- Adaptimmune plans to complete its rolling BLA submission for afami-cel in mid-2023; and with RMAT status for synovial sarcoma, the application will be eligible for ...

Yahoo | December 23, 2022

Hedge funds investors may adopt severe steps after Adaptimmune Therapeutics plc's (NASDAQ:ADAP) latest 20% drop adds to a year losses

Every investor in Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) should be aware of the most powerful shareholder groups...

Yahoo | December 10, 2022

Adaptimmune Therapeutics (ADAP) Gets a Buy from Mizuho Securities

E ratio of -2.15.

Austin Angelo on TipRanks | November 18, 2022

Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent

- Data indicate continued clinical responses with an acceptable safety profile in heavily pre-treated patients with late-stage synovial sarcoma after a single dose of afami-cel -- Overall response rate in synovial sarcoma of 39% by independent review -consistent with previous data - -Median duration of response of 50 weeks, consistent with previous data -- Afami-cel drives tumor infiltration of activated and proliferative cytotoxic ("killer") T-cells into tumors - which likely contributes to ant

Yahoo | November 18, 2022

Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Genmab (GMAB) and Adaptimmune Therapeutics (ADAP)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Moderna (MRNA – Research Report), Genmab (GMAB – Research Report) and Adaptimmune Therapeutics (ADAP – Research Report). Moderna (MRNA) Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on Moderna today and set a price target of $506.00. The company's shares closed last Monday at $179.50. According to TipRanks.

Christine Brown on TipRanks | November 14, 2022

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Celebrations may be in order for Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders, with the analysts...

Yahoo | November 13, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6345 seconds.